Ruimin Ma

927 total citations
28 papers, 687 citations indexed

About

Ruimin Ma is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ruimin Ma has authored 28 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Ruimin Ma's work include Circular RNAs in diseases (7 papers), Cancer-related molecular mechanisms research (7 papers) and MicroRNA in disease regulation (5 papers). Ruimin Ma is often cited by papers focused on Circular RNAs in diseases (7 papers), Cancer-related molecular mechanisms research (7 papers) and MicroRNA in disease regulation (5 papers). Ruimin Ma collaborates with scholars based in China, Netherlands and Israel. Ruimin Ma's co-authors include Xixiong Kang, Tao Jiang, Hong Lv, Ouchen Wang, Fan Yang, Youqun Xiang, Jiao Wang, Lin Lv, Guojun Zhang and Yue Cheng and has published in prestigious journals such as PLoS ONE, Gene and International Journal of Biological Macromolecules.

In The Last Decade

Ruimin Ma

26 papers receiving 682 citations

Peers

Ruimin Ma
Comparison fields: 5 of 79
  • Molecular Biology 456
  • Cancer Research 412
  • Oncology 120
  • Epidemiology 84
  • Surgery 44
Replace Maria Geffken with:
Maria Geffken Germany
Derek Wong Canada
Charlotte Hellmich United Kingdom
Sa’ed Akkawi Israel
Tara L. Sander United States
Anne Rowzee United States
J Górski United States
Abdolreza Daraei Iran
Karl‐Philippe Guérard Canada
Maria Geffken Germany View profile →
Citations per field, relative to Ruimin Ma
Ruimin Ma · 1×
Citations per year, relative to Ruimin Ma
Ruimin Ma · 1×

Countries citing papers authored by Ruimin Ma

Since Specialization
Citations

This map shows the geographic impact of Ruimin Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruimin Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruimin Ma more than expected).

Fields of papers citing papers by Ruimin Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruimin Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruimin Ma. The network helps show where Ruimin Ma may publish in the future.

Co-authorship network of co-authors of Ruimin Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Ruimin Ma. A scholar is included among the top collaborators of Ruimin Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruimin Ma. Ruimin Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1 0
2 0
3 1
4 5
5 12
6 14
7 20
8
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
5
9 15
10 41
11 19
12 37
13 5
14 3
15 32
16 52
17 17
18 158
19 4
20 49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026